CJC-1295
A long-acting growth-hormone-releasing hormone (GHRH) analog, often stacked with a GHRP such as ipamorelin to raise growth hormone and IGF-1. Not approved for human use.
Benefits
Why it is used: sustained elevation of GH/IGF-1 for recovery and body composition, especially paired with a GHRP. Evidence is preliminary.
Risks
Unapproved with limited human safety data; water retention, flushing, tingling, raised blood sugar, and injection-site reactions. Unregulated purity; banned in sport.
Informational only — not medical advice.
Body systems
Hormones
Research (4)
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians Mayfield et al. (2026) PubMed ↗
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Rahman et al. (2026) PubMed ↗
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Teichman et al. (2006) PubMed ↗
- Ipamorelin, the first selective growth hormone secretagogue Raun et al. (1998) PubMed ↗
Community
Log in to rate and share your notes.
No contributions yet.